CJC-1295 + Ipamorelin Blend

The CJC-1295 and Ipamorelin blend combines two complementary growth hormone secretagogues targeting the two principal GH-release signalling pathways: GHRH (growth hormone releasing hormone) and ghrelin receptor signalling. CJC-1295 (No DAC) is a modified GHRH (1-29) analogue with four amino acid substitutions (D-Ala, Gln, Leu, Ala) that confer resistance to DPP-4 degradation while retaining full GHRH receptor affinity. Upon binding the GHRH receptor (GHRHR) on pituitary somatotropes, CJC-1295 activates Galphas/cAMP/PKA signalling, stimulating growth hormone synthesis and pulsatile release. Ipamorelin is a synthetic pentapeptide that acts as a selective ghrelin receptor (GHS-R1a, growth hormone secretagogue receptor) agonist. Upon binding GHS-R1a on somatotropes, ipamorelin activates Galphaq/PLC/IP3 signalling, stimulating GH release through a pathway distinct from and complementary to the GHRH/cAMP cascade. The rationale for combination is mechanistic complementarity: GHRH and ghrelin receptor agonism activate partially distinct intracellular signalling cascades in the same target cell (somatotrope), producing amplified, pulsatile GH release when combined. Ipamorelin's selectivity for the ghrelin receptor (with minimal cortisol, prolactin, or ACTH interaction) makes the blend a clean research tool for studying the integrated GHRH-ghrelin axis in GH secretagogue signalling.